Circio Holding ASA

Circio signs research license with Lonza

Oslo, Norway 11 April 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology

company developing powerful circular mRNA technology for next generation nucleic

acid medicine, today announces that its subsidiary Circio AB has entered a

research evaluation agreement with Lonza, one of the world's largest contract

development and manufacturing organizations.

The research license enables Circio to test the circVec circular mRNA expression

technology in Lonza's proprietary transient expression system for protein

production. Further updates will follow as necessary as the project progresses.

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Neil Hunter - Hunter PR

Phone:+44 7821 255568 (http://tel:+447821255568)

About Circio

Building next generation RNA technology for nucleic acid medicine

Circio Holding ASA is a biotechnology company developing powerful circular RNA

vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression

platform for novel DNA, RNA and viral therapeutics. The proprietary circVec

technology is based on a modular genetic cassette design for efficient

biogenesis of multifunctional circRNA inside cells, which can be deployed in

multiple therapeutic settings, including genetic medicine, cell therapy and

chronic disease. The circVec platform has demonstrated up to 15-fold enhanced

and more significantly more durable protein expression vs. classic mRNA vector

systems and has the potential to become a new gold-standard platform technology

for nucleic acid and viral therapeutics in the future. The circRNA R&D

activities are being conducted by the wholly owned subsidiary Circio AB based at

the Karolinska Institute in Stockholm, Sweden.

AI Terminal